Zacks Research Issues Negative Forecast for TBPH Earnings

Theravance Biopharma, Inc. (NASDAQ:TBPH - Free Report) - Equities research analysts at Zacks Research cut their Q1 2026 EPS estimates for Theravance Biopharma in a note issued to investors on Wednesday, February 26th. Zacks Research analyst R. Department now expects that the biopharmaceutical company will post earnings of ($0.38) per share for the quarter, down from their prior estimate of ($0.21). The consensus estimate for Theravance Biopharma's current full-year earnings is ($1.09) per share. Zacks Research also issued estimates for Theravance Biopharma's Q2 2026 earnings at ($0.37) EPS and Q3 2026 earnings at ($0.07) EPS.

Separately, HC Wainwright reiterated a "buy" rating and set a $15.00 target price on shares of Theravance Biopharma in a report on Tuesday, February 25th. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $13.75.

Theravance Biopharma Trading Up 0.0 %

NASDAQ:TBPH traded up $0.00 on Monday, hitting $9.72. 89,710 shares of the stock were exchanged, compared to its average volume of 241,992. The stock has a fifty day moving average of $9.30 and a 200-day moving average of $8.95. The stock has a market cap of $478.17 million, a PE ratio of -9.63 and a beta of 0.21. Theravance Biopharma has a fifty-two week low of $7.44 and a fifty-two week high of $10.90.

Remove Ads

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last released its quarterly earnings data on Wednesday, February 26th. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.26). Theravance Biopharma had a negative return on equity of 24.79% and a negative net margin of 78.18%. The firm had revenue of $18.75 million for the quarter, compared to analyst estimates of $29.90 million.

Institutional Trading of Theravance Biopharma

Several large investors have recently bought and sold shares of TBPH. Newtyn Management LLC boosted its stake in shares of Theravance Biopharma by 5.7% in the fourth quarter. Newtyn Management LLC now owns 4,757,403 shares of the biopharmaceutical company's stock valued at $44,767,000 after purchasing an additional 258,337 shares during the period. BNP Paribas Financial Markets boosted its position in Theravance Biopharma by 88.9% in the 3rd quarter. BNP Paribas Financial Markets now owns 305,480 shares of the biopharmaceutical company's stock valued at $2,462,000 after buying an additional 143,781 shares during the last quarter. Algert Global LLC acquired a new stake in shares of Theravance Biopharma during the third quarter valued at about $851,000. Dimensional Fund Advisors LP increased its position in shares of Theravance Biopharma by 20.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 553,713 shares of the biopharmaceutical company's stock worth $5,211,000 after acquiring an additional 95,304 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Theravance Biopharma by 71.1% in the fourth quarter. Millennium Management LLC now owns 192,839 shares of the biopharmaceutical company's stock worth $1,815,000 after acquiring an additional 80,140 shares in the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Insiders Place Their Bets

In related news, SVP Rhonda Farnum sold 4,000 shares of the business's stock in a transaction that occurred on Tuesday, January 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the transaction, the senior vice president now directly owns 309,565 shares of the company's stock, valued at approximately $2,786,085. The trade was a 1.28 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 6.90% of the stock is currently owned by insiders.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.